Add to ORKGAlthough low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab.status: publishe
OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for u...
BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to tre...
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade)...
Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with...
Background: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab ...
Background and aims: Intensification of the infliximab (IFX) regimen is recommended if the treatment...
OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) a...
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...
Objectives: To evaluate the effect of immunomodulators on formation of antibodies to infliximab (ATI...
Background: Antibodies to infliximab [ATI] and trough levels to infliximab [TRI] are associated with...
peer reviewedBACKGROUND & AIMS: A combination of infliximab and immunomodulators is the most efficac...
International audienceBACKGROUND:Antibodies to infliximab [ATI] and trough levels to infliximab [TRI...
Background & Aims: In the TAILORIX trial, no benefit could be shown by infliximab dose escalation ba...
International audienceBackground & aims: Infliximab increases the risk of infection in patients with...
Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...
OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for u...
BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to tre...
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade)...
Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with...
Background: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab ...
Background and aims: Intensification of the infliximab (IFX) regimen is recommended if the treatment...
OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) a...
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...
Objectives: To evaluate the effect of immunomodulators on formation of antibodies to infliximab (ATI...
Background: Antibodies to infliximab [ATI] and trough levels to infliximab [TRI] are associated with...
peer reviewedBACKGROUND & AIMS: A combination of infliximab and immunomodulators is the most efficac...
International audienceBACKGROUND:Antibodies to infliximab [ATI] and trough levels to infliximab [TRI...
Background & Aims: In the TAILORIX trial, no benefit could be shown by infliximab dose escalation ba...
International audienceBackground & aims: Infliximab increases the risk of infection in patients with...
Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...
OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for u...
BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to tre...
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade)...